Kata Kunci
Systemic Lupus Erythematosus
Therapeutic Target
Cara Mengutip
Abstrak
Introduction: Systemic Lupus Erythematosus is an autoimmune disorder in which the immune system becomes increasingly dysregulated, inflamed, and involves multiple organ systems. While NETs play an essential role in antimicrobial defence, in SLE, they enhance immunopathological damage by driving type I interferon response, autoantibody production, and tissue damage. NETs, due to their unique capability of serving both as disease extraditional and as disease instigators, are a promising target in SLE. Methods: The current review is in accordance with PRISMA guidelines and registered in PROSPERO (CRD420251129386). Comprehensive searches were performed in PubMed, ScienceDirect, SpringerLink, and JSTOR, published between 2021 and 2025. Primary research investigating NETs or interventions aimed at them in SLE were included. Articles were excluded for non-originality, focus outside SLE and NETs, and lack of therapeutic focus. Documents were appraised for design, population, sample size, intervention, outcome, and therapeutic relevance for extraction. Results: A total of 1.065 articles were initially identified, of which six studies met inclusion criteria. Clinical studies consistently demonstrated elevated NET remnants, impaired NET degradation, and organ-specific deposition associated with lupus nephritis and vascular involvement. Preclinical models showed that PAD4 inhibition, DNase I supplementation, and mitochondrial-targeted antioxidants reduced NET formation, attenuated interferon-driven immune responses, and ameliorated renal and vascular pathology. Conclusion: Existing data underscore the role of NETs as critical pathogenic components of SLE and corroborate the possibility of NETs as therapeutic targets. There is, however, an immediate need for bespoke NET assays, active-signed NET biomarker stratification, NET-guided patient stratification, and rigorous clinical trial design.
Referensi
Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56(11):1945–1961. doi.org/10.1093/rheumatology/kex260
Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745. doi.org/10.1136/annrheumdis-2019-215213
Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134–147. doi.org/10.1038/nri.2017.105
Knight JS, Kaplan MJ. Pathogenic functions of neutrophil extracellular traps in inflammatory and autoimmune diseases. Nat Rev Rheumatol. 2023;19(2):97–113. doi.org/10.1038/s41584-022-00847-3
Leffler J, Martin M, Gullstrand B, Tydén H, Lood C, Truedsson L, Bengtsson AA, Blom AM. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol. 2019;200(6):2167–2175. doi.org/10.4049/jimmunol.1701573
Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2017;114(36):E9613–E9622. https://doi.org/10.1073/pnas.1702926114
Carmona-Rivera C, Zhao W, Yalavarthi S, Kaplan MJ. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through activation of matrix metalloproteinase-2. Ann Rheum Dis. 2017;76(3):577–584. https://doi.org/10.1136/annrheumdis-2016-209352
Knight JS, Luo W, Subramanian S, O'Dell AA, Yalavarthi S, Thompson PR, Kaplan MJ. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine lupus. J Clin Invest. 2021;131(4):e140807. https://doi.org/10.1172/JCI140807
Zhang W, Wang Y, Kong Y, Fang D, Xu J, Liu Y, Huang X. Mitochondrial ROS Scavenger MitoTEMPO Attenuates Autoimmune Phenotypes in Lupus-Prone MRL/lpr Mice. Oxid Med Cell Longev. 2019;2019:1892410. https://doi.org/10.1155/2019/1892410
Bangs SC, Knight JS, Kaplan MJ. Targeting neutrophil extracellular traps in systemic autoimmune disease. Nat Rev Drug Discov. 2023;22(3):183–200. https://doi.org/10.1038/s41573-022-00572-w
Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016;22(2):146-153. https://doi.org/10.1038/nm.4027
Liu L, de Leeuw K, van Goor H, Doornbos-van der Meer B, Arends S, Westra J. Neutrophil extracellular traps and oxidative stress in systemic lupus erythematosus patients with and without renal involvement. Arthritis Res Ther. 2024;26:220. https://doi.org/10.1186/s13075-024-03454-y
Stabach PR, Hakkim A, Knight JS, Carmona-Rivera C, Kaplan MJ. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. JCI Insight. 2024;9(14):e177003. https://doi.org/10.1172/jci.insight.177003
Wang Q, Ma Y, Liu Y, Xu Q, Zhang Y, Wang Y, et al. Diverse roles of NETosis in the pathogenesis of lupus. Front Immunol. 2022;13:895216. https://doi.org/10.3389/fimmu.2022.895216
Shi H, Zuo Y, Yalavarthi S, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in autoimmune diseases. Nat Rev Rheumatol. 2022;18(12):761-775. https://doi.org/10.1038/s41584-022-00881-2
Reshetnyak T, Nurbaeva K. The role of NETs in the pathogenesis of SLE and antiphospholipid syndrome. Int J Mol Sci. 2023;24(17):13581. https://doi.org/10.3390/ijms241713581
Knight JS, Zhao W, Luo W, Subramanian V, O’Dell AA, Yalavarthi S, et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest. 2013;123(7):2981-2993. https://doi.org/10.1172/JCI67390
Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532-1535. https://doi.org/10.1126/science.1092385
Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in lupus. J Immunol. 2011;187(1):538-552. https://doi.org/10.4049/jimmunol.1100450
Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010;107(21):9813-9818. https://doi.org/10.1073/pnas.0909927107
Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra20. https://doi.org/10.1126/scitranslmed.3001201
Leffler J, Gullstrand B, Jönsen A, Nilsson JA, Martin M, Blom AM, et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2013;15(4):R84. https://doi.org/10.1186/ar4264
Carmona-Rivera C, Zhao W, Yalavarthi S, Kaplan MJ. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis. 2015;74(7):1417-1424. https://doi.org/10.1136/annrheumdis-2013-204837
Delgado-Rizo V, Martínez-Guzmán MA, Iñiguez-Gutierrez L, García-Orozco A, Alvarado-Navarro A, Fafutis-Morris M. Neutrophil extracellular traps and its implications in inflammation: An overview. Front Immunol. 2017;8:81. https://doi.org/10.3389/fimmu.2017.00081
Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13(4):463-469. https://doi.org/10.1038/nm1565
Kessenbrock K, Krumbholz M, Schönermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623-625. https://doi.org/10.1038/nm.1959
Sur Chowdhury C, Giaglis S, Walker UA, Buser A, Hahn S, Hasler P. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: Analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther. 2014;16(3):R122. https://doi.org/10.1186/ar4579
Garcia-Baena B, Morales-Sánchez A, Fernández-Ruiz M, Pego-Reigosa JM, Vilas-Blanco M, Campos-Caro A, et al. NETosis markers as disease activity indicators in systemic lupus erythematosus and lupus nephritis patients. Lupus. 2021;30(13):2075-2086. https://doi.org/10.1177/09612033211040348
Wirestam L, Schierbeck H, Skogh T, Gunnarsson I, Ottas A, Sundén-Cullberg J, et al. High mobility group box protein 1 in complex with DNA promotes the development of lupus nephritis. Arthritis Rheumatol. 2020;72(6):1053-1063. https://doi.org/10.1002/art.41198
Leffler J, Martin M, Gullstrand B, Tydén H, Lood C, Truedsson L, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol. 2012;188(7):3522-3531. https://doi.org/10.4049/jimmunol.1102404
Hakkim A, Abraha A, Nishi H, Urban CF, Brinkmann V, Heppner FL, et al. Regulation of neutrophil extracellular trap formation by anti-oxidants. Blood. 2011;117(23):6378-6387. https://doi.org/10.1182/blood-2010-10-312926
Soderberg D, Segelmark M. Neutrophil extracellular traps in vasculitis, friend or foe? Curr Opin Rheumatol. 2018;30(1):16-23. https://doi.org/10.1097/BOR.0000000000000454
Midon MJ, Martinez-Ara J, Vazquez-Mateo C, Fernandez-Rodriguez CM, Garcia-Gonzalez MA, Vazquez-Mellado A, et al. Mitochondrial oxidative stress drives NETosis in systemic lupus erythematosus. Front Immunol. 2021;12:628705. https://doi.org/10.3389/fimmu.2021.628705
Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013;5(178):178ra40. https://doi.org/10.1126/scitranslmed.3005580
Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood. 2012;120(15):3007-3018. https://doi.org/10.1182/blood-2012-03-416156
Kaplan MJ, Radic M. Neutrophil extracellular traps: Double-edged swords of innate immunity. J Immunol. 2012;189(6):2689-2695. https://doi.org/10.4049/jimmunol.1201719
Psarras A, Alase A, Antanaviciute A, Carr IM, Md Yusof MY, Wittmann M, et al. Functionally distinct neutrophil subsets in human systemic lupus erythematosus reveal specific dysregulation in low-density granulocytes. Front Immunol. 2020;11:441. https://doi.org/10.3389/fimmu.2020.00441
Carlucci PM, Purmalek MM, Dey AK, Temesgen-Oyelakin Y, Sakhardande S, Joshi AA, et al. Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. JCI Insight. 2018;3(8):e99276. https://doi.org/10.1172/jci.insight.99276
Kim SJ, Park YJ, Lee JY, Hwang JH, Choe JY, Park SH, et al. Mitochondrial ROS and mitochondrial DNA promote the generation of pro-inflammatory low-density granulocytes in lupus. Arthritis Res Ther. 2018;20:250. https://doi.org/10.1186/s13075-018-1742-0
Smith CK, Kaplan MJ. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol. 2015;27(5):448-453. https://doi.org/10.1097/BOR.0000000000000197
Gupta AK, Joshi MB, Philippova M, Erne P, Hasler P, Hahn S, et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Lett. 2010;584(14):3193-3197. https://doi.org/10.1016/j.febslet.2010.06.006
Pieterse E, Rother N, Yanginlar C, Gerretsen J, Boeltz S, Munoz LE, et al. Cleaved N-terminal histone tails distinguish between NADPH oxidase (NOX)-dependent and NOX-independent pathways of neutrophil extracellular trap formation. Ann Rheum Dis. 2018;77(12):1790-1798. https://doi.org/10.1136/annrheumdis-2018-213223
Carmona-Rivera C, Carlucci PM, Goel RR, James E, Brooks SR, Rims C, et al. Neutrophil extracellular traps mediate articular cartilage damage and enhance cartilage component immunogenicity in rheumatoid arthritis. JCI Insight. 2020;5(13):e139388. https://doi.org/10.1172/jci.insight.139388
Lee KH, Kronbichler A, Park DDY, Park Y, Moon H, Kim H, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: A comprehensive review. Autoimmun Rev. 2017;16(11):1160-1173. https://doi.org/10.1016/j.autrev.2017.09.012
Yousefi S, Mihalache C, Kozlowski E, Schmid I, Simon HU. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. Cell Death Differ. 2009;16(11):1438-1444. https://doi.org/10.1038/cdd.2009.96
Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA–peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra19. https://doi.org/10.1126/scitranslmed.3001180
Apel F, Zychlinsky A, Kenny EF. The role of neutrophil extracellular traps in rheumatic diseases. Nat Rev Rheumatol. 2018;14(8):467-475. https://doi.org/10.1038/s41584-018-0039-z
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus (TULIP-2). N Engl J Med. 2020;382(3):211-221. https://doi.org/10.1056/NEJMoa1912196
Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208-e219. https://doi.org/10.1016/S2665-9913(19)30076-1
Strand V, Levy RA, Cervera R, Nikolov NP, Petri MA, Furie RA, et al. Patient-reported outcomes with anifrolumab in moderate to severe SLE: post-hoc analysis of TULIP-1 and TULIP-2. Lancet Rheumatol. 2022;4(4):e240-e251. https://doi.org/10.1016/S2665-9913(22)00029-7
Hartl D, Khademi M, Ferrara G, Senn L, Eberhardt CS, Keller M, et al. Neutrophil extracellular traps in immunothrombosis and beyond. Nat Rev Immunol. 2022;22(6):394-410. https://doi.org/10.1038/s41577-020-00481-6
Serpas L, Evans K, Zhang R, Sarkar P, McDonald B, Speir M, et al. Autoantibody-mediated impairment of DNASE1L3 activity in sporadic SLE. J Exp Med. 2021;218(4):e20201138. https://doi.org/10.1084/jem.20201138
Sisirak V, Sally B, D’Agati V, Martinez-Ortiz W, Ozcakar ZB, David J, et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell. 2016;166(1):88-101. https://doi.org/10.1016/j.cell.2016.05.034
Jiménez-Alcázar M, Rangaswamy C, Panda R, Bitterling J, Simsek YJ, Long AT, et al. Host DNases prevent vascular occlusion by neutrophil extracellular traps. Blood. 2017;129(10):1357-1365. https://doi.org/10.1182/blood-2016-07-730614
Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107(36):15880-15885. https://doi.org/10.1073/pnas.1005743107
Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. J Exp Med. 2012;209(11):2119-2133. https://doi.org/10.1084/jem.20120353
Lewis HD, Liddle J, Coote JE, Atkinson SJ, Barker MD, Bax BD, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Sci Rep. 2015;5:9793. https://doi.org/10.1038/srep09793
Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. J Clin Invest. 2020;130(11):6151-6157. https://doi.org/10.1172/JCI138999
Farrera C, Fadeel B. Macrophage clearance of neutrophil extracellular traps is a silent process. J Immunol. 2013;191(5):2647-2656. https://doi.org/10.4049/jimmunol.1300436
Leffler J, Stojanovich L, Shoenfeld Y, Bogdanovic G, Hesselstrand R, Blom AM. Degradation of NETs by DNase I and C1q in SLE. Autoimmunity. 2012;45(8):586-591. https://doi.org/10.3109/08916934.2012.719949
Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine in rheumatic diseases. Nat Rev Rheumatol. 2020;16(3):155-166. https://doi.org/10.1038/s41584-020-0372-x
Wirestam L, Arve S, Larsson R, Enocsson H. The role of HMGB1 in SLE and lupus nephritis. Autoimmun Rev. 2022;21(10):103127. https://doi.org/10.1016/j.autrev.2022.103127
Goel RR, Wang X, O’Neil LJ, Nakabo S, Hasneen K, Gupta S, et al. Interferon lambda promotes immune dysregulation and tissue inflammation in SLE. Nature. 2022;603(7900):102-108. https://doi.org/10.1038/s41586-021-04370-5
Artikel ini berlisensi Creative Commons Attribution 4.0 International License.
Hak Cipta (c) 2025 Penulis dan Jurnal